Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis

Journal of Bone and Mineral Research

Volumn 13, Issue 4, 1998, Pages 731-738

  Guañabens, Nuria ^a,b   Parés, Albert ^a   Alvarez, Luisa ^a   Martínez De Osaba, Ma Jesús ^a   Monegal, Ana ^a   Peris, Pilar ^a   Ballesta, Antonio M ^a   Rodés, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; COLLAGEN TYPE 1; HYDROXYPROLINE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LIVER FIBROSIS; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; FEMALE; HUMANS; HYDROXYPROLINE; ISOENZYMES; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; MIDDLE AGED; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 2642684537     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.4.731     Document Type: Article

References (43)

1. Calvo MS, Eyre DR, Gundberg CM 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:333-368.
2. 3 treatment. Gastroenterology 83:97-102.
3. Herlong HF, Recker RR, Maddrey WC 1982 Bone disease in primary biliary cirrhosis: Histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83:103-108.
4. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL 1985 Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103:855-860.
5. Lindor KD 1993 Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis. Semin Liver Dis 13:367-373.
6. Schuppan D 1990 Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Semin Liver Dis 10:1-10.
7. Seyer JM, Hutcheson ET, Kang AH 1977 Collagen polymorphism in normal and cirrhotic human liver. J Clin Invest 59:241-248.
8. Ludwig J, Dickson ER, McDonald GSA 1978 Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Path Anat Histol 379:103-110.
9. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D 1997 Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390-406.
10. Savolainen ER, Goldberg B, Leo MA, Velez M, Lieber CS 1984 Diagnostic value of serum procollagen peptide measure-ments in alcoholic liver disease. Alcohol: Clin Exp Res 8: 384-389.
11. Galambos MR, Collins DC, Galambos JT 1985 A radioimmunoassay procedure for type III procollagen: Its use in the detection of hepatic fibrosis. Hepatology 5:38-42.
12. Torres M, Parés A, Caballería J, Bruguera M, Jiménez W, Heredia D, Ballesta AM, Rodés J 1986 El péptido aminoterminal del procolágeno tipo III como índice de fibrosis hepáica en los alcohólicos crónicos. Gastroenterol Hepatol 9:111-115.
13. Torres M, Parés A, Caballería J, Jiménez W, Heredia D, Bruguera M, Rodés J 1986 Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. Gastroenterology 90:1241-1246.
14. Ericksson S, Zettervall O 1986 The N-terminal propeptide of collagen type III in serum as a prognostic indicator in primary biliary cirrhosis. J Hepatol 2:370-378.
15. Babbs C, Hunt LP, Haboubi NY, Smith H, Rowan BP, Warnes TW 1988 Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet 1:1021-1024.
16. Salmerón JM, Caballería J, Parés A, Caballería L, Bruguera M, Rodés J 1989 El péptido aminoterminal del procolágeno tipo III en la cirrosis biliar primaria. Significado clínico y valor pronóstico. Gastroenterol Hepatol 12:109-113.
17. Maruyama K, Feinman L, Fainsilber Z, Nakano M, Okazaki I, Lieber CS 1982 Mammalian collagenase increases in early alcoholic liver disease and decreases with cirrhosis. Life Sci 30:1379-1384.
18. Arthur MJP 1995 Collagenases and liver fibrosis. J Hepatol 22 (Suppl 2):43-48.
19. Guañabens N, Parés A, Mariñoso L, Brancós MA, Piera C, Serrano S, Rivera F, Rodés J 1990 Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 85:1356-1362.
20. Stellon AJ, Webb A, Compston J, Williams R 1987 Low bone turnover state in primary biliary cirrhosis. Hepatology 7:137-142.
21. Smedsrod B, Melkko J, Risteli L, Risteli J 1990 Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345-350.
22. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrod B 1994 Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179:405-412.
23. Hartmann DJ, Trinchet JC, Ricard-Blum S, Beaugrand R, Callard P, Ville G 1990 Radioimmunoassays of type I collagen that mainly detects degradation products in serum: Application to patients with liver diseases. Clin Chem 36:421-426.
24. Gallouni A, Plebani M, Pontisso P, Chemello L, Masiero M, Mantovani G, Alberti A 1994 Serum markers of hepatic fibrogenesis in chronic hepatitis C treated with alfa-2 interferon. Liver 14:257-264.
25. Lau KHW, Onishi T, Wergedal JE, Singer FR, Baylink DJ 1987Characterization and assay of tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption. Clin Chem 33:458-462.
26. Rico H, Villa LF 1993 Serum tartrate-resistant acid phosphatase (TRAP) as biochemical marker of bone remodeling. Calcif Tissue Int 52:149-150.
27. Halleen J, Hentunen TA, Hellman J, Vaananen HK 1996 Tartrate-resistant acid phosphatase from human bone: Purification and development of an immunoassay. J Bone Miner Res 11:1444-1452.
28. Cuthbert JA, Pak CYC, Zerwekh JE, Glass KD, Combes B 1984 Bone disease in primary biliary cirrhosis: Increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4:1-8.
29. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL 1993 Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 14:819-827.
30. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD 1990 Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-96.
31. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C 1991 Urinary excretion of pyridinoline correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639-644.
32. Eastell R, Colwell A, Hampton L, Reeve J 1997 Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 12:59-65.
33. Eyre DR 1995 The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 66 (Suppl 266):166-170.
34. Hayasaka A, Ilda S, Suzuki N, Kondo F, Miyazaki M, Yonemitsu H 1996 Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. J Hepatol 24:692-698.
35. Ricard-Blum S, Bresson-Hadni S, Vuitton DA, Ville G, Grimaud JA 1992 Hydroxypyridium collagen cross-links in human liver fibrosis: Study of alveolar echinococcosis. Hepatology 15:599-602.
36. Seibel MJ, Schmidt-Gayk H, Stracke H, Burckhardt P 1993 Biochemical markers of bone metabolism are affected by non-skeletal diseases involving collagen turnover. J Bone Miner Res 8 (Suppl 1):S287.
37. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258.
38. Apone S, Fevold K, Lee M, Eyre D 1994 A rapid method for quantifying osteoclast activity in vitro. J Bone Miner Res 9 (Suppl 1):S178.
39. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
40. Garnero P, Ginetys E, Riou JP, Delmas PD 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785.
41. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1995 Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868.
42. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C 1997 Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12:1028-1034.
43. Guañabens N, Parés A, Monegal A, Peris P, Pons F, Alvarez L, Martínez de Osaba MJ, Roca M, Torra M, Rodés J 1997 Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after two years. Gastroenterology 113:219-224.